Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04752020 · ClinicalTrials.gov registry record · Early Phase 1
Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty
A Early Phase 1 study, sponsored by Massachusetts Eye and Ear Infirmary.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 25
- Enrollment target
NCT04752020 is a Early Phase 1 study that has completed, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 25 participants.
The verdict
NCT04752020, a Early Phase 1 study, has completed, sponsored by Massachusetts Eye and Ear Infirmary.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This will be a prospective assessment of whether adjuvant Netarsudil use in patients undergoing Descemetorhexis without endothelial keratoplasty improves time to corneal clearance and post-operative central endothelial cell counts. The anticipated enrollment is 25 patients.
Interventions
- DRUG Netarsudil Ophthalmic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-03-28 |
| Est. Completion | 2023-12-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04752020
The ClinicalTrials.gov registry entry for NCT04752020 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts Eye and Ear Infirmary, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Netarsudil Ophthalmic is the first listed.
NCT04752020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04752020 about?
NCT04752020 is a clinical study titled "Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty". This will be a prospective assessment of whether adjuvant Netarsudil use in patients undergoing Descemetorhexis without endothelial keratoplasty improves time to corneal clearance and post-operative central endothelial cell counts. The anticipated enrollment is 25 patients.
What is the current status of trial NCT04752020?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 25 participants. The study started on 2021-03-28. Estimated completion is 2023-12-30.
What interventions are being tested in trial NCT04752020?
The interventions under investigation include: Netarsudil Ophthalmic (DRUG).
Who is sponsoring clinical trial NCT04752020?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.